$2.17
+0.0000%Forian Inc. provides software solutions, proprietary data driven insights, and predictive analytics to optimize the operational, clinical, and financial performance of its healthcare, cannabis, and government customers. It operates through three segments: Information & Software, Services, and Other. The company's products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides clients with a presentation of business performance. Its products also comprise BioTrack seed-to-sale compliance traceability platform, which is used to manage the tracking and tracing of various cannabis products from cultivation to sale; BioTrack State Traceability & Enforcement Monitoring System to ensure transparency and accountability throughout cannabis supply chain; and STEMS, a seed-to-sale tracking module, to provide cannabis program management solution to cannabis regulatory agencies. In addition, the company offers security monitoring and web marketing services. The company is headquartered in Newtown, Pennsylvania.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
FORA โข NASDAQ
| Forian Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
30.3M | 20.2M | 20.5M | 16.4M | 16.9M | 544.9K | 0.0 | |
GROSS PROFIT | |||||||
(14.4M) | (7.3M) | (5.5M) | (5M) | (4.7M) | (38.3K) | (854.0) | |
15.9M | 12.8M | 15M | 11.4M | 12.2M | 506.6K | -854.0 | |
OPERATING INCOME | |||||||
(18.4M) | (19.8M) | (20.6M) | (30.3M) | (39.8M) | (5.5M) | (1.3M) | |
(15.4M) | (16.9M) | (18.5M) | (20.8M) | (27.6M) | (2.1M) | (463.8K) | |
(2.9M) | (1.4M) | (1.4M) | (4M) | (9M) | (2.5M) | (827.5K) | |
-2.5M | -7M | -5.6M | -19M | -27.6M | -5M | -1.3M | |
PRE-TAX INCOME | |||||||
(142.4K) | (708.9K) | (834.8K) | (846.1K) | (322.4K) | (0.0) | (0.0) | |
1.1M | 1.7M | 1.5M | -579.9K | -315.6K | 3.6K | 0.0 | |
(0.0) | (1.5M) | (674.3K) | (5.5M) | (3.2M) | (872K) | (0.0) | |
-177.4K | 3.3M | 7.4M | -215.2K | 1.1M | 3.6K | 3.3K | |
-2.6M | -3.7M | 1.8M | -19.2M | -26.5M | -5M | -1.3M | |
NET INCOME | |||||||
(228K) | (66.6K) | (85.7K) | (24K) | (22.5K) | (0.0) | -4.0 | |
-2.9M | -3.8M | 11.1M | -26M | -26.6M | -5M | -1.3M |
FORA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 15, 2026 | March 31, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 03, 2026 | April 02, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 08, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | December 15, 2025 | January 08, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 14, 2025 | November 14, 2025 | 2025 |
Continue your FORA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.